Reduced frequency and severity of infusion-related adverse events after change in ofatumumab infusion regimen: comment on the article by Østergaard et al.
Abeles
Aryeh M
AM
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000628:therapy; D004311:Double-Blind Method; D006801:Humans; D007262:Infusions, Intravenous / Q000009:adverse effects*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; C527517:ofatumumab